Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : T-cell entities : Novartis ag save search
Global CAR T-Cell Therapy Market Analysis Report 2023: Drug type, Indication, Target Antigen, End-user and Region - Forecast to 2030
Published: 2024-01-24 (Crawled : 17:00) - prnewswire.com
PFE | News 4 | $25.805 -1.77% 3.8M
|
Health Technology
|
| O: 0.39%
H: 0.82%
C: -0.74%
NVS | News | $98.67 0.33% 260K
|
Health Technology
|
| O: 0.22%
H: 0.43%
C: -0.39%
SRNE | $0.02 97K
|
Health Technology
|
| O: -63.33%
H: 263.64%
C: 127.27%
GILD | $66.69 -0.58% 850K
|
Health Technology
|
| O: 0.1%
H: 0.43%
C: -0.04%
AUTL | $4.105 -2.49% 770K
|
Health Technology
|
| O: -0.91%
H: 11.52%
C: 4.94%
drug report t-cell global therapy market
T-cell Therapy Market Size to Grow USD US$ 76.6 billion from 2023-2033 | Says Transparency Market Research Inc.
Published: 2023-11-06 (Crawled : 15:00) - prnewswire.com
NVS | News | $98.67 0.33% 260K
|
Health Technology
|
| O: 0.54%
H: 0.73%
C: 0.2%
t-cell research therapy market
Cell Therapy Market to grow by USD 31.04 billion from 2022 to 2027 | Proven effectiveness of CAR T-cell therapy boosts the market - Technavio
Published: 2023-10-04 (Crawled : 18:00) - prnewswire.com
LSTA | $2.83 310
|
Manufacturing
|
| O: 3.86%
H: 0.93%
C: -2.33%
ALPMY | News | $9.47 400K
|
Manufacturing
|
| O: 0.59%
H: 0.29%
C: 0.22%
NVS | News | $98.67 0.33% 260K
|
Health Technology
|
| O: -1.21%
H: 1.3%
C: 1.16%
BCLI A | $0.545 49K
|
Health Technology
|
| O: -0.37%
H: 10.94%
C: -4.38%
t-cell cell therapy market
CAR T-Cell Therapy Market size to grow at a CAGR of 13.44% from 2022 to 2027; Growing Awareness Regarding CAR T-cell Therapy to boost the market growth- Technavio.
Published: 2023-08-09 (Crawled : 08:00) - prnewswire.com
GLAXF | News | $19.54 -3.77% 0
|
Health Technology
|
| O: 1.92%
H: 0.0%
C: 0.0%
NVSEF | News | $96.0 52K
|
Health Technology
|
| O: 1.11%
H: 0.53%
C: 0.53%
NVS | News | $98.67 0.33% 260K
|
Health Technology
|
| O: -0.07%
H: 0.73%
C: 0.36%
GSK | News | $40.93 0.17% 170K
|
Health Technology
|
| O: 0.14%
H: 0.8%
C: 0.43%
GILD | $66.69 -0.58% 850K
|
Health Technology
|
| O: 0.61%
H: 1.07%
C: -0.5%
AUTL | $4.105 -2.49% 770K
|
Health Technology
|
| O: -2.02%
H: 3.44%
C: 2.75%
t-cell growing therapy market
T-cell lymphoma Market 2026, Growing Geriatric Population to Boost Growth - Technavio
Published: 2022-09-26 (Crawled : 06:00) - prnewswire.com
SNYNF | News | $94.0 -0.27% 0
|
Health Technology
|
| O: 5.77%
H: 0.0%
C: -2.27%
AZNCF | News | $135.35 400
|
Health Technology
|
| O: -1.15%
H: 0.0%
C: -2.43%
NVS | News | $98.67 0.33% 260K
|
Health Technology
|
| O: -2.04%
H: 0.82%
C: 0.2%
BAX | $40.35 -1.42% 220K
|
Health Technology
|
| O: -0.45%
H: 0.6%
C: -0.45%
ABBV | News | $166.41 -0.83% 860K
|
Health Technology
|
| O: -0.69%
H: 0.51%
C: -0.61%
SNY | News | $49.085 5.31% 1.2M
|
Health Technology
|
| O: -2.29%
H: 0.35%
C: -0.67%
BIIB | $198.365 -1.8% 310K
|
Health Technology
|
| O: -0.17%
H: 1.2%
C: -0.86%
AUTL | $4.105 -2.49% 770K
|
Health Technology
|
| O: 2.94%
H: 1.43%
C: -0.48%
AZN | News | $75.37 5.86% 2.7M
|
Health Technology
|
| O: -1.52%
H: 0.48%
C: -1.36%
growing t-cell growth market
Worldwide T-cell Lymphoma Industry to 2028 - Featuring Genmab, Seagen and GlaxoSmithKline Among Others
Published: 2022-04-28 (Crawled : 21:00) - prnewswire.com
GNMSF | News | $290.34 0.23% 0
|
Health Technology
|
| O: 2.93%
H: 1.47%
C: 1.33%
GLAXF | News | $19.54 -3.77% 0
|
Health Technology
|
| O: -0.45%
H: 0.0%
C: 0.0%
NVSEF | News | $96.0 52K
|
Health Technology
|
| O: -1.05%
H: 0.0%
C: -0.99%
NVS | News | $98.67 0.33% 260K
|
Health Technology
|
| O: 0.19%
H: 0.59%
C: -1.36%
GSK | News | $40.93 0.17% 170K
|
Health Technology
|
| O: 0.89%
H: 0.0%
C: 0.0%
BMY | $45.36 -7.16% 10M
|
Health Technology
|
| O: -3.61%
H: 3.02%
C: 2.02%
BHC | $8.52 -0.47% 230K
|
Health Technology
|
| O: -1.67%
H: 0.0%
C: 0.0%
GMAB | News | $27.69 -2.74% 53K
|
Health Technology
|
| O: 1.4%
H: 0.82%
C: -1.07%
t-cell
Novartis receives positive CHMP opinion for Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma in Europe
Published: 2022-03-25 (Crawled : 12:20) - globenewswire.com
NVS | News | $98.67 0.33% 260K
|
Health Technology
|
| O: 1.14%
H: 0.0%
C: 0.0%
kymriah novartis europe car-t positive therapy chmp t-cell
Outlook on the CAR T-cell Therapy Global Market to 2031 - by Product Type, Indications, End-user and Region
Published: 2022-01-14 (Crawled : 14:00) - prnewswire.com
NVSEF | News | $96.0 52K
|
Health Technology
|
| O: 1.26%
H: 0.0%
C: 0.0%
NVS | News | $98.67 0.33% 260K
|
Health Technology
|
| O: 0.02%
H: 0.0%
C: 0.0%
JNJ | News | $147.46 -0.72% 820K
|
Health Technology
|
| O: -0.53%
H: 0.0%
C: 0.0%
SRNE | $0.02 97K
|
Health Technology
|
| O: -5.96%
H: 0.0%
C: 0.0%
GILD | $66.69 -0.58% 850K
|
Health Technology
|
| O: -0.32%
H: 0.0%
C: 0.0%
BLUE | $0.9046 -1.98% 1.4M
|
Health Technology
|
| O: -0.57%
H: 0.0%
C: 0.0%
cel therapy t-cell
Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Research Report 2021: Analysis of Yescarta, Tecartus, Kymriah, Breyanzi, & Abecma
Published: 2021-12-24 (Crawled : 14:00) - prnewswire.com
NVSEF | News | $96.0 52K
|
Health Technology
| Email alert
Add to watchlist
ABBV | News | $166.41 -0.83% 860K
|
Health Technology
| Email alert
Add to watchlist
NVS | News | $98.67 0.33% 260K
|
Health Technology
| Email alert
Add to watchlist
CYAD | $0.47 -12.49% 49K
|
Health Technology
| Email alert
Add to watchlist
yescarta research kymriah cel therapy t-cell
NeoImmuneTech Announces First Patient Dosed in Phase 1b Study of NT-I7 (efineptakin alfa) and Kymriah® (tisagenlecleucel) in Relapsed/Refractory Large B-Cell Lymphoma
Published: 2021-10-13 (Crawled : 12:00) - biospace.com/
NVS | News | $98.67 0.33% 260K
|
Health Technology
|
| O: 0.46%
H: 0.62%
C: 0.08%
phase 1 phase 1b t-cell phase 2b
Global CAR-T Cell Therapy Markets to 2026: Rising Clinical Trials and Development of New and Effective Therapy Options
Published: 2021-09-28 (Crawled : 16:00) - prnewswire.com
NVSEF | News | $96.0 52K
|
Health Technology
|
| O: -0.12%
H: 1.77%
C: -0.99%
NVS | News | $98.67 0.33% 260K
|
Health Technology
|
| O: 0.16%
H: 0.04%
C: -0.51%
JNJ | News | $147.46 -0.72% 820K
|
Health Technology
|
| O: -0.04%
H: 0.5%
C: -0.18%
ABBV | News | $166.41 -0.83% 860K
|
Health Technology
|
| O: -0.09%
H: 0.93%
C: -0.26%
SGMO | News | $0.4802 -2.6% 200K
|
Health Technology
|
| O: -1.12%
H: 0.52%
C: -2.17%
AUTL | $4.105 -2.49% 770K
|
Health Technology
|
| O: -2.67%
H: 1.27%
C: -5.48%
AMGN | News | $271.635 -0.5% 120K
|
Health Technology
|
| O: -0.38%
H: 1.16%
C: -0.01%
clinical trials therapy car-t trials trial t-cell
Novartis provides update on BELINDA study investigating Kymriah® as second-line treatment in aggressive B-cell non-Hodgkin lymphoma
Published: 2021-08-24 (Crawled : 06:00) - globenewswire.com
NVS | News | $98.67 0.33% 260K
|
Health Technology
|
| O: -0.67%
H: 0.0%
C: -1.04%
treatment t-cell
Gainers vs Losers
| 44% | 56% |
Top 10 Gainers
SGBX | $0.26 80.43% 54M
|
Producer Manufacturing
LICN | $1.0 78.57% 3.3M
|
CSSE 4 | $0.2656 74.39% 9.7M
|
Consumer Services
BRFH 4 | $1.89 71.82% 32M
|
Manufacturing
BOF | $1.95 66.67% 920K
|
MTC | $3.62 61.61% 790K
|
Technology Services
AMST | $3.13 56.5% 500K
|
Technology Services
PCSA | $2.28 40.74% 37M
|
Producer Manufacturing
EVA | $0.626 39.14% 2.3M
|
Process Industries
OPTN | $1.215 31.31% 12M
|
Health Services
Your saved searches
Save your searches and get alerts when important news are released.